A 4-month rifampin regimen was found to be cheaper than a 9-month course of isoniazid for the treatment of latent tuberculosis in a cost-comparison study published in the Annals of Internal Medicine. Currently, isoniazid is the standard of treatment in most countries for latent tuberculosis infection. The finding that 4 months rifampin treatment is cheaper adds to previously published evidence that this treatment is as effective, while also significantly safer and more likely to be completed, than 6 months or 9 months isoniazid treatment. These findings have the potential to change the way latent tuberculosis is treated.

The World Health Organization (WHO) is convening a Guideline Development Group (GDG) to advise on updates needed to its recommendations on the systematic screening for tuberculosis (TB).

The rate of new active tuberculosis (TB) diagnoses among people living with HIV in the UK is disproportionately high among people of black African ethnicity, investigators report in the online edition of AIDS.

WHO releases updated guidelines for the treatment of drug-resistant TB.

The resistance profiles of patients with drug-resistant tuberculosis may be useful in developing treatment plans for household contacts, according to a new study that examined the concordance of drug resistance profiles among household members.

Study by the Universities of Bonn and Nijmegen explains how BCG vaccination reduces susceptibility to infections

UNIVERSITY PARK, Pa. — The number of human tuberculosis (TB) cases that are due to transmission from animals, as opposed to human-to-human transmission, may be much higher than previously estimated, according to an international team of researchers. The results could have implications for epidemiological studies and public health interventions.

CAPE TOWN, SOUTH AFRICA —Living with HIV or active tuberculosis (TB) increases a person’s likelihood of dying from COVID-19, preliminary data from South Africa show. However, the effect is small compared with other known risk factors such as old age and diabetes.

The tuberculosis pathogen Mycobacterium tuberculosis can protect itself better when combined and thus stay alive longer in the air. This was the result of a study by the Leibniz Research Alliance INFECTIONS, which was published in the scientific journal Scientific Reports on Monday.

11 June 2020, Geneva, Switzerland– The Stop TB Partnership’s Global Drug Facility (GDF) today announced the addition of child-friendly bedaquiline 20 mg tablets to the GDF Pediatric DR-TB Initiative. The US FDA approval of the medicine, on 27 May 2020, marks a new milestone for all-oral DR-TB regimens in children who are older than 5 years of age and weighing more than 15 kilograms. These children will now benefit from the same optimized treatments being provided to their parents – no more injections for anyone.